Literature DB >> 20501514

Use of the proportion of patients dying on an End of Life Pathway as a quality marker: considerations for interpretation.

Edwin J Pugh1, Mel McEvoy, John Blenkinsopp.   

Abstract

The Department of Health as part of its End of Life Care Strategy has developed a set of markers as a quality of care proxy for adults at the end of life. 'The number/proportion of patients dying with the Liverpool Care Pathway (or equivalent) in place' is suggested as a quality metric for all care providers. A retrospective audit of uptake of use of the Liverpool Care Pathway (LCP) in an NHS hospital in the North of England showed that 39% of all patients who died had been placed on the LCP. Overall 58% of patients who died were judged to meet the criteria for LCP use. This represented 81% of patients dying with cancer as a primary cause compared to 51% of patients dying with non-cancer. This difference was statistically very significant. In the Trust under study, 67% of dying patients who fulfilled the LCP criteria were placed on the pathway. The results of this study suggest that a simple percentage of deaths on the pathway is an unsophisticated statistic which needs to be interpreted with care. In particular it will be influenced by the proportion of people dying with cancer or non-cancer. This should be considered particularly when presenting the results to the public and to healthcare stakeholders or when making comparisons between provider organizations.

Entities:  

Mesh:

Year:  2010        PMID: 20501514     DOI: 10.1177/0269216310368579

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  2 in total

1.  Variation in medication use in cancer patients at the end of life: a cross-sectional analysis.

Authors:  N J H Raijmakers; L van Zuylen; C J Furst; M Beccaro; L Maiorana; P Pilastri; C Rossi; G Flego; A van der Heide; M Costantini
Journal:  Support Care Cancer       Date:  2012-10-14       Impact factor: 3.603

2.  Why is the Liverpool care pathway used for some dying cancer patients and not others? Healthcare professionals' perspectives.

Authors:  Alison Freemantle; Jane Seymour
Journal:  BMC Res Notes       Date:  2012-09-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.